Differential Expression of Alternatively Spliced c-erbB-2 mRNA in Primary Tumors, Lymph Node Metastases, and Bone Marrow Micrometastases from Breast Cancer Patients

1998 ◽  
Vol 247 (2) ◽  
pp. 319-323 ◽  
Author(s):  
Frank Gebhardt ◽  
Kurt S. Zänker ◽  
Burkhard Brandt
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Metastases ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Bone Marrow Micrometastases ◽  
Alternatively Spliced ◽  
Node Metastases

Do Bone Marrow Micrometastases Correlate with Sentinel Lymph Node Metastases in Breast Cancer Patients?

2005 ◽  
Vol 200 (5) ◽  
pp. 720-725 ◽  
Author(s):  
Susan M. Trocciola ◽  
Syed Hoda ◽  
Michael P. Osborne ◽  
Paul J. Christos ◽  
Heather Levin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Metastases ◽  
Breast Cancer Patients ◽  
Bone Marrow Micrometastases ◽  
Node Metastases

Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients

1998 ◽  
Vol 22 (2) ◽  
pp. 122-129 ◽  
Author(s):  
Nikos Pandis ◽  
Manuel R. Teixeira ◽  
Adewale Adeyinka ◽  
Helen Rizou ◽  
Georgia Bardi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Metastases ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Node Metastases

scholarly journals High Levels of Expression of Cartilage Oligomeric Matrix Protein in Lymph Node Metastases in Breast Cancer Are Associated with Reduced Survival

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5876
Author(s):  
Konstantinos S. Papadakos ◽  
Catharina Hagerling ◽  
Lisa Rydén ◽  
Anna-Maria Larsson ◽  
Anna M. Blom
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Metastases ◽  
Matrix Protein ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Node Metastases

Cartilage oligomeric matrix protein (COMP) is a regulator of the extracellular matrix and is expressed primarily in the cartilage. Recently, COMP expression was also documented in breast cancer patients both in sera and tumor biopsies, in both of which it could serve as an independent prognostic marker. This study aimed to assess COMP as a potential biomarker in the group of metastatic breast cancer patients. Levels of COMP were measured by ELISA in serum samples of 141 metastatic breast cancer patients. Biopsies from primary tumors, synchronous lymph node metastases, and distant metastases were stained for COMP expression. The levels of serum COMP were higher in patients with ER- and HER2-positive tumors when compared to triple-negative tumors and correlated with the presence of bone and lung metastases, circulating tumor cell count, and clusters. Most of the primary tumors expressing COMP (70%) retained the expression also in the lymph node metastases, which correlated with visceral metastases and reduced survival. In conclusion, COMP appears as a valuable biomarker in metastatic breast cancer patients indicating a more severe stage of the disease. Serum COMP levels were associated with specific types of metastases in patients with metastatic breast cancer emphasizing that further studies are warranted to elucidate its potential role as a monitoring marker.

Sign in / Sign up

Export Citation Format

Share Document